CRVS · Corvus Pharmaceuticals, Inc.

On April 22, 2026, the Board of Directors of Corvus Pharmaceuticals, acting upon the recommendation of the Nominating and Corporate Governance Committee, appointed Andrew C. Chan, M.D., Ph.D., as a Class II director. His term will expire at the 2027 annual meeting of stockholders. Dr. Chan was also appointed to the Nominating Committee. Under the Company's non-employee director compensation program, Dr. Chan will receive a $35,000 annual retainer for Board service and an automatic initial stock option grant to purchase 30,000 shares of Common Stock under the 2016 Equity Incentive Award Plan. He will also receive an additional $4,000 annual retainer for his service on the Nominating Committee. Concurrently, Scott Morrison notified the Company of his intention to resign from the Board, effective April 23, 2026. The Company acknowledged Mr. Morrison's significant contributions over more than a decade of service, specifically noting his leadership as Chairperson of the Audit Committee.